Latest (49) Full Text Articles (1570) Focus on GERD Article Summary

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
Gastroenterology, 01/24/2014  Clinical Article

Zeuzem S, et al. – The authors performed a phase IIb, randomized, double–blind, placebo–controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon–α2a (PegIFN), and ribavirin (RBV) in patients with hepatitis C virus (HCV) genotype–1 infection previously treated with PegIFN and RBV. In treatment–experienced patients, 12, 24, or 48 weeks simeprevir (100 mg or 150 mg once daily) in combination with 48 weeks PegIFN and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, and RBV and was generally well tolerated.


  • The authors analyzed data from patients who did not respond (null response), had a partial response, or relapsed after treatment with PegIFN and RBV, randomly assigned to receive simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks (n = 396), or placebo plus PegIFN and RBV for 48 weeks (n = 66).
  • All patients were followed for 24 weeks after planned end of treatment; the primary end point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA) at that time point.


  • Overall, rates of SVR at 24 weeks were significantly higher in the groups given simeprevir than those given placebo (61%-80% vs 23%; P < .001), regardless of prior response to PegIFN and RBV (simeprevir vs placebo: prior null response, 38%-59% vs 19%; prior partial response, 48%-86% vs 9%; prior relapse, 77%-89% vs 37%).
  • All groups had comparable numbers of adverse events; these led to discontinuation of simeprevir or placebo and/or PegIFN and RBV in 8.8% of patients given simeprevir and 4.5% of those given placebo.

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from PDR - powered by MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top Articles of 2014

1 New hope for devastating metabolic disorder Duke-NUS Graduate Medical School Singapore News, November 24, 2015

2 Long-term outcomes of thalidomide therapy for adults with refractory Crohn’s disease Clinical Gastroenterology and Hepatology , November 19, 2015    Clinical Article

3 Simple blood test measures risk of liver cancer Flanders Institute for Biotechnology (VIB) News, November 2, 2015

4 Study: New drug combo may cure hepatitis C in even the sickest patients Baylor Health Care System, November 20, 2015

5 NTU scientists use dead bacteria to kill colorectal cancer Nanyang Technological University News, November 11, 2015

6 Unexpected health benefits of coffee revealed Monash University News, November 19, 2015

7 Vitamin C halts growth of aggressive forms of colorectal cancer in preclinical study Weill Cornell Medical College News, November 11, 2015

8 Diabetes drug could be used to combat fatty liver disease, research shows University of Birmingham Medical News, November 23, 2015

9 Discovery could lead to new way to combat deadly effects of diarrhea UF Health, October 29, 2015

10 Multistate foodborne disease outbreaks sicken thousands, highlight need for action Full Text CDC, November 5, 2015    Free full text

11 Zinc intake and risk of Crohn’s disease and ulcerative colitis: a prospective cohort study International Journal of Epidemiology, November 9, 2015    Review Article

12 Gut bacteria can dramatically amplify cancer immunotherapy The University of Chicago Medical Center News, November 9, 2015

13 Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study The Lancet, November 20, 2015    Clinical Article

14 Sausages with antioxidants from berries to prevent cancer Lund University News, November 16, 2015

15 Self-medication with steroids in inflammatory bowel disease Digestive and Liver Diseases, November 25, 2015    Clinical Article

16 Diffusion-weighted MR imaging of pancreatic cancer and inflammation: Prognostic significance of pancreatic inflammation in pancreatic cancer patients Pancreatology, November 12, 2015    Clinical Article

17 Virus-specific CD4+ T cells have functional and phenotypic characteristics of follicular T-helper cells in patients with acute and chronic HCV infections Gastroenterology, November 19, 2015    Clinical Article

18 Inherited determinants of Crohn's disease and ulcerative colitis phenotypes The Lancet, October 28, 2015    Clinical Article

19 Obesity in adolescents with intellectual disability: Prevalence and associated characteristics Obesity Research & Clinical Practice, November 9, 2015    Review Article

20 Predicting and optimising response to anti-TNF therapy in Crohn's disease – algorithm for practical management Alimentary Pharmacology and Therapeutics, November 4, 2015    Review Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Register now to view all our site's content (FREE)!

View Samples and Register